Second primary cancer in survivors following concurrent chemoradiation for locally advanced non-small-cell lung cancer

N Takigawa, K Kiura, Y Segawa, Y Watanabe, H Kamei, T Moritaka, T Shibayama, H Ueoka, K Gemba, T Yonei, M Tabata, T Shinkai (+5 others)
2006 British Journal of Cancer  
Long-term cancer survivors risk development of second primary cancers (SPC). Vigilant follow-up may be required. We report outcomes of 92 patients who underwent chemoradiation for unresectable stage III non-small-cell lung cancer, with a median followup of 8.9 years. The incidence of SPC was 2.4 per 100 patient-years (95% confidence interval: 1.0 -4.9).
doi:10.1038/sj.bjc.6603422 pmid:17031394 pmcid:PMC2360581 fatcat:s6x5xp3vmjckhpqitm2jq3twja